Marinomed announces preliminary sales for 2021, the highest in its history

DGAP-News: Marinomed Biotech AG / Tag(s): Preliminary results
27.01.2022 / 07:45
The issuer is solely responsible for the content of this announcement.

Marinomed announces preliminary sales for 2021, the highest in its history

Korneuburg, Austria, January 27, 2022 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company that globally markets therapeutic products derived from innovative proprietary technology platforms, today announced preliminary earnings for 2021. rose 43% to €11.6 million, the highest in Marinomed history. This increase reflects the continued strong demand for carrageenan products as well as the initial payment of the collaboration and license agreement with the Chinese company Luoxin Pharmaceutical Group Co., Ltd., for Budesolv, a nasal spray based on budesonide.

“The past year has been very successful. With our first agreement for a product candidate derived from Marinosolv, Budesolv, we have reached a new milestone for our business. Additionally, we have launched Solv^4U make Marinosolv available to partner companies and support them in the development of effective formulations for their active pharmaceutical ingredients. Additionally, we received clinical confirmation from an independent study that our Carragelose virus blocker can significantly reduce the number of COVID-19 cases, and we were able to show that Carragelose continues to be effective against several variants of concern.” , Dr. Andreas Grassauer, CEO of Marinomed, noted. “We have thus achieved our guidance for 2021 and are now in an excellent position for future projects in 2022. We will focus on Marinosolv-derived therapies, which will be key value drivers for us on our long-term growth trajectory. .

About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian science-based biotechnology company that commercializes therapeutic products globally. Marinomed focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv^(R) The technology increases the solubility and bioavailability of poorly soluble compounds in aqueous formulations. Under the Solv brand^4UMarinomed provides formulation development based on the Marinosolv^(R) technology for external partners. carrageenan^(R) The platform includes innovative patent-protected products targeting viral respiratory tract infections and may also reduce the risk of SARS-CoV-2 infection. carrageenan^(R) is used as a virus blocker in nasal sprays, throat sprays and lozenges, which are sold through international partners in more than 40 countries. Marinomed, Marinosolv^(R) and carrageenan^(R) are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in certain locations only. The company is based in Korneuburg, Austria, and listed on the Prime Market of the Vienna Stock Exchange (VSE: MARI). Further information is available at https://www.marinomed.com.

For more information, contact:

Warning
This press release contains forward-looking statements based on the current opinions, expectations and projections of the management of Marinomed Biotech AG regarding future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, these statements. The current opinions, expectations and projections of the management of Marinomed Biotech AG can be identified by the context of such statements or words such as “anticipate”, “believe”, “estimate”, “expect”, “have the intention to”, “plan”, “project” and “target”. Forward-looking statements speak only as of the date they are made, and Marinomed Biotech AG undertakes no obligation to update, review or revise any forward-looking statements contained in this press release, whether as a result of new information, future developments or otherwise.

27.01.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de